

NAGLAZYME- galsulfase solution
BioMarin Pharmaceutical Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NAGLAZYME® safely and effectively. See full prescribing information for NAGLAZYME.

NAGLAZYME (galsulfase) injection for intravenous use

Initial U.S. Approval: 2005

RECENT MAJOR CHANGES-----

Warnings and Precautions, Spinal or Cervical Cord Compression (5.6) 3/2013

INDICATIONS AND USAGE-----

NAGLAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity (1).

DOSAGE AND ADMINISTRATION-----

1 mg per kg of body weight administered once weekly as an intravenous infusion (2).

DOSAGE FORMS AND STRENGTHS-----

Injection: 5 mg per 5 mL vial (3).

CONTRAINDICATIONS-----

None (4).

WARNINGS AND PRECAUTIONS-----

- **Anaphylaxis and Allergic Reactions:** Life-threatening anaphylactic reactions have been observed in some patients during NAGLAZYME infusions and up to 24 hours after infusion. If anaphylaxis or severe allergic reactions occur, immediately discontinue infusion and initiate appropriate treatment, which may include resuscitation, epinephrine, administering additional antihistamines, antipyretics or corticosteroids (5.1).
- **Immune-mediated Reactions:** Immune-mediated reactions can occur with NAGLAZYME. Monitor patients for the development of immune complex-mediated reactions while receiving NAGLAZYME (5.2).
- **Risk of Acute Cardiorespiratory Failure:** Caution should be exercised when administering NAGLAZYME to patients susceptible to fluid volume overload. Consider a decreased total infusion volume and infusion rate when administering NAGLAZYME to these patients. Appropriate medical monitoring and support measures should be available during infusion (2.1, 5.3).
- **Acute Respiratory Complications:** Sleep apnea is common in MPS VI patients and antihistamine pretreatment may increase the risk of apneic episodes. Appropriate respiratory support should be available during infusion (5.4).
- **Infusion Reactions:** Pretreatment with antihistamines with or without antipyretics is recommended prior to the start of infusion to reduce the risk of infusion-reactions. If infusion reactions occur, decreasing the infusion rate, temporarily stopping the infusion, or administering additional antihistamines and/or antipyretics is recommended (2.1, 5.5).

ADVERSE REACTIONS-----

The most common adverse reactions (≥10%) are: rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain and dyspnea. The most common adverse reactions requiring interventions are infusion-related reactions (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact: BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or go to www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS-----

- **Pregnancy and Nursing Mothers:** Clinical Surveillance Program available (8.1, 8.3, 17.2).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2013

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

2.2 Instructions for Use

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylaxis and Allergic Reactions

5.2 Immune-mediated Reactions

5.3 Risk of Acute Cardiorespiratory Failure

5.4 Acute Respiratory Complications Associated with Administration

5.5 Infusion Reactions

5.6 Spinal or Cervical Cord Compression

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Immunogenicity

6.3 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

17.1 Infusion Reactions

17.2 Clinical Surveillance Program

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

NAGLAZYME (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

The recommended dosage regimen of NAGLAZYME is 1 mg per kg of body weight administered once weekly as an intravenous infusion.

Pretreatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes prior to

the start of the infusion [see *Warnings and Precautions (5.2)*].

The total volume of the infusion should be delivered over a period of time of no less than 4 hours. NAGLAZYME should be diluted with 0.9% Sodium Chloride Injection, USP, to a final volume of 250 mL and delivered by controlled intravenous infusion using an infusion pump. The initial infusion rate should be 6 mL per hour for the first hour. If the infusion is well tolerated, the rate of infusion may be increased to 80 mL per hour for the remaining 3 hours. The infusion time can be extended up to 20 hours if infusion reactions occur.

For patients 20 kg and under or those who are susceptible to fluid volume overload, physicians may consider diluting NAGLAZYME in a volume of 100 mL [see *Warnings and Precautions (5.1)* and *Adverse Reactions (6.3)*]. The infusion rate (mL per hour) should be decreased so that the total infusion duration remains no less than 4 hours.

Each vial of NAGLAZYME provides 5 mg of galsulfase (expressed as protein content) in 5 mL of solution and is intended for single use only. Do not use the vial more than one time. The concentrated solution for infusion must be diluted with 0.9% Sodium Chloride Injection, USP, using aseptic techniques. Prepare Naglazyme using low-protein-binding containers and administer the diluted NAGLAZYME solution to patients using a low-protein-binding infusion set equipped with a low-protein-binding 0.2 µm in-line filter. There is no information on the compatibility of diluted NAGLAZYME with glass containers.

2.2 Instructions for Use

Prepare and use NAGLAZYME according to the following steps. Use aseptic techniques.

- a. Determine the number of vials to be used based on the patient's weight and the recommended dose of 1 mg per kg:

$$\text{Patient's weight (kg)} \times 1 \text{ mL/kg of NAGLAZYME} = \text{Total number of mL of NAGLAZYME}$$

$$\text{Total number of mL of NAGLAZYME} \div 5 \text{ mL per vial} = \text{Total number of vials}$$

Round up to the next whole vial. Remove the required number of vials from the refrigerator to allow them to reach room temperature. Do not allow vials to remain at room temperature longer than 24 hours prior to dilution. Do not heat or microwave vials.

- b. Before withdrawing the NAGLAZYME solution from the vial, visually inspect each vial for particulate matter and discoloration. The NAGLAZYME solution should be clear to slightly opalescent and colorless to pale yellow. Some translucency may be present in the solution. Do not use if the solution is discolored or if there is particulate matter in the solution.
- c. From a 250 mL infusion bag of 0.9% Sodium Chloride Injection, USP, withdraw and discard a volume equal to the volume of NAGLAZYME solution to be added. If using a 100 mL infusion bag, this step is not necessary.
- d. Slowly withdraw the calculated volume of NAGLAZYME from the appropriate number of vials using caution to avoid excessive agitation. Do not use a filter needle, as this may cause agitation. Agitation may denature NAGLAZYME, rendering it biologically inactive.
- e. Slowly add the NAGLAZYME solution to the 0.9% Sodium Chloride Injection, USP, using care to avoid agitation of the solutions. Do not use a filter needle.
- f. Gently rotate the infusion bag to ensure proper distribution of NAGLAZYME. Do not shake the solution.

- g. Administer the diluted NAGLAZYME solution to patients using a low-protein-binding infusion set equipped with a low-protein-binding 0.2 µm in-line filter.

NAGLAZYME does not contain preservatives; therefore, after dilution with saline, the infusion bags should be used immediately. If immediate use is not possible, the diluted solution must be stored refrigerated at 2°C to 8°C (36°F to 46°F) and administered within 48 hours from the time of dilution to completion of administration. Other than during infusion, do not store the diluted NAGLAZYME solution at room temperature. Any unused product or waste material must be discarded and disposed of in accordance with local requirements.

NAGLAZYME must not be infused with other products in the infusion tubing. The compatibility of NAGLAZYME in solution with other products has not been evaluated.

3 DOSAGE FORMS AND STRENGTHS

Injection; 5 mL vials (5 mg per 5 mL).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylaxis and Allergic Reactions

Anaphylaxis and severe allergic reactions have been observed in patients during and up to 24 hours after NAGLAZYME infusion. Some of the reactions were life-threatening and included anaphylaxis, shock, respiratory distress, dyspnea, bronchospasm, laryngeal edema, and hypotension. If anaphylaxis or other severe allergic reactions occur, NAGLAZYME should be immediately discontinued, and appropriate medical treatment should be initiated. In patients who have experienced anaphylaxis or other severe allergic reactions during infusion with NAGLAZYME, caution should be exercised upon rechallenge; appropriately trained personnel and equipment for emergency resuscitation (including epinephrine) should be available during infusion [*see Adverse Reactions (6)*].

5.2 Immune-mediated Reactions

Type III immune complex-mediated reactions, including membranous glomerulonephritis have been observed with NAGLAZYME, as with other enzyme replacement therapies. If immune-mediated reactions occur, discontinuation of the administration of NAGLAZYME should be considered, and appropriate medical treatment initiated. The risks and benefits of re-administering NAGLAZYME following an immune-mediated reaction should be considered. Some patients have successfully been rechallenged and have continued to receive NAGLAZYME under close clinical supervision [*see Adverse Reactions (6.3)*].

5.3 Risk of Acute Cardiorespiratory Failure

Caution should be exercised when administering NAGLAZYME to patients susceptible to fluid volume overload; such as in patients weighing 20 kg or less, patients with acute underlying respiratory illness, or patients with compromised cardiac and/or respiratory function, because congestive heart failure may result. Appropriate medical support and monitoring measures should be readily available during NAGLAZYME infusion, and some patients may require prolonged observation times that should be based on the individual needs of the patient [*see Adverse Reactions (6.3)*].

5.4 Acute Respiratory Complications Associated with Administration

Sleep apnea is common in MPS VI patients and antihistamine pretreatment may increase the risk of apneic

episodes. Evaluation of airway patency should be considered prior to initiation of treatment. Patients using supplemental oxygen or continuous positive airway pressure (CPAP) during sleep should have these treatments readily available during infusion in the event of an infusion reaction, or extreme drowsiness/sleep induced by antihistamine use.

Consider delaying NAGLAZYME infusions in patients who present with an acute febrile or respiratory illness because of the possibility of acute respiratory compromise during infusion of NAGLAZYME.

5.5 Infusion Reactions

Because of the potential for infusion reactions, patients should receive antihistamines with or without antipyretics prior to infusion. Despite routine pretreatment with antihistamines, infusion reactions, some severe, occurred in 33 of 59 (56%) patients treated with NAGLAZYME. Serious adverse reactions during infusion included laryngeal edema, apnea, pyrexia, urticaria, respiratory distress, angioedema, and anaphylactoid reaction. Severe adverse reactions included urticaria, chest pain, rash, dyspnea, apnea, laryngeal edema, and conjunctivitis [see *Adverse Reactions (6)*].

The most common symptoms of drug-related infusion reactions were pyrexia, chills, rash, urticaria, dyspnea, nausea, vomiting, pruritis, erythema, abdominal pain, hypertension, and headache. Respiratory distress, chest pain, hypotension, angioedema, conjunctivitis, tremor, and cough were also reported. Infusion reactions began as early as Week 1 and as late as Week 146 of NAGLAZYME treatment. Twenty-three of 33 patients (70%) experienced recurrent infusion reactions during multiple infusions though not always in consecutive weeks.

Symptoms typically abated with slowing or temporary interruption of the infusion and administration of additional antihistamines, antipyretics, and occasionally corticosteroids. Most patients were able to complete their infusions. Subsequent infusions were managed with a slower rate of NAGLAZYME administration, treatment with additional prophylactic antihistamines, and, in the event of a more severe reaction, treatment with prophylactic corticosteroids.

If severe infusion reactions occur, immediately discontinue the infusion of NAGLAZYME and initiate appropriate treatment. The risks and benefits of re-administering NAGLAZYME following a severe reaction should be considered.

No factors were identified that predisposed patients to infusion reactions. There was no association between severity of infusion reactions and titer of anti-galsulfase antibodies.

5.6 Spinal or Cervical Cord Compression

Spinal or cervical cord compression (SCC) with resultant myelopathy is a known and serious complication of MPS VI. SCC is expected to occur in the natural history of the disease, including in patients on NAGLAZYME. There have been post-marketing reports of patients treated with NAGLAZYME who experienced the onset or worsening of SCC requiring decompression surgery. Patients with MPS VI should be monitored for signs and symptoms of spinal/cervical cord compression (including back pain, paralysis of limbs below the level of compression, urinary and fecal incontinence) and given appropriate clinical care.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates observed in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

NAGLAZYME was studied in a randomized, double-blind, placebo-controlled trial in which 19 patients received weekly infusions of 1 mg/kg NAGLAZYME and 20 patients received placebo; of the 39 patients 66% were female, and 62% were White, non-Hispanic. Patients were aged 5 years to 29

years. NAGLAZYME-treated patients were approximately 3 years older than placebo-treated patients (mean age 13.7 years versus 10.7 years, respectively).

Serious adverse reactions experienced in this trial include apnea, pyrexia, and respiratory distress. Severe adverse reactions include chest pain, dyspnea, laryngeal edema, and conjunctivitis. The most common adverse reactions requiring interventions were infusion reactions.

Table 1 summarizes the adverse reactions that occurred in the placebo-controlled trial in at least 2 patients more in the NAGLAZYME-treated group than in the placebo-treated group.

Table 1: Adverse Reactions that Occurred in the Placebo-Controlled Trial in at least 2 Patients More in the NAGLAZYME Group than in the Placebo Group

MedDRA Preferred Term	NAGLAZYME (n = 19)	Placebo (n = 20*)
	No. Patients (%)	No. Patients (%)
All	19 (100)	20 (100)
Abdominal Pain	9 (47)	7 (35)
Ear Pain	8 (42)	4 (20)
Arthralgia	8 (42)	5 (25)
Pain	6 (32)	1 (5)
Conjunctivitis	4 (21)	0
Dyspnea	4 (21)	2 (10)
Rash	4 (21)	2 (10)
Chills	4 (21)	0
Chest Pain	3 (16)	1 (5)
Pharyngitis	2 (11)	0
Areflexia	2 (11)	0
Corneal Opacity	2 (11)	0
Gastroenteritis	2 (11)	0
Hypertension	2 (11)	0
Malaise	2 (11)	0
Nasal Congestion	2 (11)	0
Umbilical Hernia	2 (11)	0
Hearing Impairment	2 (11)	0

* One of the 20 patients in the placebo group dropped out after Week 4 infusion

Four open-label clinical trials were conducted in MPS VI patients aged 3 months to 29 years with NAGLAZYME administered at doses of 0.2 mg/kg (n = 2), 1 mg/kg (n = 55), and 2 mg/kg (n = 2). The mean exposure to the recommended dose of NAGLAZYME (1 mg/kg) was 138 weeks (range = 54 to 261 weeks). Two infants (12.1 months and 12.7 months) were exposed to 2 mg/kg of NAGLAZYME for 105 and 81 weeks, respectively.

In addition to those listed in Table 1, common adverse reactions observed in the open-label trials include pruritus, urticaria, pyrexia, headache, nausea, and vomiting. The most common adverse reactions requiring interventions were infusion reactions. Serious adverse reactions included laryngeal edema, urticaria, angioedema, and other allergic reactions. Severe adverse reactions included urticaria, rash, and abdominal pain.

Observed adverse events in four open-label studies (up to 261 weeks treatment) were not different in nature or severity to those observed in the placebo-controlled study. No patients discontinued during open-label treatment with NAGLAZYME due to adverse events.

6.2 Immunogenicity

Ninety-eight percent (53/54) of patients treated with NAGLAZYME and evaluable for the presence of antibodies to galsulfase developed anti-galsulfase IgG antibodies within 4 to 8 weeks of treatment (in four clinical studies). In 19 patients treated with NAGLAZYME from the placebo-controlled study, serum samples were evaluated for a potential relationship of anti-galsulfase antibody development to clinical outcome measures. All 19 patients treated with NAGLAZYME developed antibodies specific to galsulfase; however, the analysis revealed no consistent predictive relationship between total antibody titer, neutralizing or IgE antibodies, and infusion-associated reactions, urinary glycosaminoglycan (GAG) levels, or endurance measures. Antibodies were assessed for the ability to inhibit enzymatic activity but not cellular uptake.

The data reflect the percentage of patients whose test results were considered positive for antibodies to galsulfase using specific assays and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibodies in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to galsulfase with the incidence of antibodies to other products may be misleading.

6.3 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of NAGLAZYME. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In addition to infusion reactions reported in clinical trials, serious reactions which occurred during NAGLAZYME infusion in the worldwide marketing experience include anaphylaxis, shock, hypotension, bronchospasm, and respiratory failure.

Additional infusion reactions included pyrexia, erythema, pallor, bradycardia, tachycardia, hypoxia, cyanosis, tachypnea, and paresthesia.

During postmarketing surveillance, there has been a single case of membranous nephropathy and rare cases of thrombocytopenia reported. In the case of membranous nephropathy, renal biopsy revealed galsulfase-immunoglobulin complexes in the glomeruli. With both membranous nephropathy and thrombocytopenia, patients have been successfully rechallenged and have continued to receive NAGLAZYME.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B.

Adequate and well-controlled studies have not been conducted with NAGLAZYME in pregnant women. Reproduction studies have been performed in rats at intravenous doses up to 3 mg/kg/day (about 0.5 times the recommended human dose of 1 mg/kg based on the body surface area) and in rabbits at intravenous doses up to 3 mg/kg/day (about 0.97 times the recommended human dose of 1 mg/kg based on the body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to NAGLAZYME. NAGLAZYME should be used during pregnancy only if clearly needed.

Pregnant women with MPS VI who are treated with NAGLAZYME should be encouraged to enroll in the MPS VI Clinical Surveillance Program at **800-983-4587** [*see Patient Counseling Information (17.2)*].

8.3 Nursing Mothers

It is not known whether NAGLAZYME is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NAGLAZYME is administered to a nursing mother.

Nursing mothers with MPS VI who are treated with NAGLAZYME should be encouraged to enroll in the MPS VI Clinical Surveillance Program at **800-983-4587** [see *Patient Counseling Information (17.2)*].

8.4 Pediatric Use

Clinical studies with NAGLAZYME were conducted in 56 patients, ages 5 to 29 years, with the majority of these patients in the pediatric age group [see *Clinical Studies (14)*]. In addition, an open-label study was conducted in four infants (3 months to 12.7 months) treated with 1 mg/kg (n = 2) or 2 mg/kg (n = 2) of NAGLAZYME. Safety results in infants were consistent with results observed in patients 5 to 29 years old [see *Adverse Reactions (6)*].

8.5 Geriatric Use

Clinical studies of NAGLAZYME did not include patients older than 29 years of age. It is not known whether older patients respond differently from younger patients.

11 DESCRIPTION

NAGLAZYME is a formulation of galsulfase, which is a purified human enzyme that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Galsulfase (glycosaminoglycan *N*-acetylgalactosamine 4-sulfatase, EC 3.1.6.12) is a lysosomal enzyme that catalyzes the cleavage of the sulfate ester from terminal *N*-acetylgalactosamine 4-sulfate residues of glycosaminoglycans (GAG), chondroitin 4-sulfate and dermatan sulfate.

Galsulfase is a glycoprotein with a molecular weight of approximately 56 kDa. The recombinant protein consists of 495 amino acids and possesses six asparagine-linked glycosylation sites, four of which carry a bis-mannose-6-phosphate residue for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue, C α -formylglycine, which is required for enzyme activity. NAGLAZYME has a specific activity of approximately 70 units per mg of protein content. One activity unit is defined as the amount of enzyme required to convert 1 micromole of 4-methylumbelliferyl sulfate to 4-methylumbelliferone and free sulfate per minute at 37°C.

NAGLAZYME is intended for intravenous infusion and is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted with 0.9% Sodium Chloride Injection, USP, prior to administration. NAGLAZYME is supplied in clear Type I glass 5 mL vials.

Each vial provides 5 mg galsulfase, 43.8 mg sodium chloride, 6.20 mg sodium phosphate monobasic monohydrate, 1.34 mg sodium phosphate dibasic heptahydrate, and 0.25 mg polysorbate 80 in a 5 mL extractable solution with pH of approximately 5.8. NAGLAZYME does not contain preservatives. Each vial is for single use only.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. MPS VI is characterized by the absence or marked reduction in *N*-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate, dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. NAGLAZYME is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of galsulfase to specific mannose-6-phosphate receptors.

12.2 Pharmacodynamics

The responsiveness of urinary GAG to dosage alterations of NAGLAZYME is unknown, and the

relationship of urinary GAG to other measures of clinical response has not been established. No association was observed between antibody development and urinary GAG levels [see *Adverse Reactions* (6.2)].

12.3 Pharmacokinetics

The pharmacokinetic parameters of galsulfase were evaluated in 13 patients with MPS VI who received 1 mg/kg of NAGLAZYME as a weekly 4-hour infusion for 24 weeks. The pharmacokinetic parameters at Week 1 and Week 24 are shown in Table 2.

Table 2: Pharmacokinetic Parameters (Median, Range)

Pharmacokinetic Parameter	Week 1	Week 24
C _{max} (mcg/mL)	0.8 (0.4 to 1.3)	1.5 (0.2 to 5.5)
AUC _{0-t} (hr•mcg/mL)*	2.3 (1.0 to 3.5)	4.3 (0.3 to 14.2)
V _z (mL/kg)	103 (56 to 323)	69 (59 to 2,799)
CL (mL/kg/min)	7.2 (4.7 to 10.5)	3.7 (1.1 to 55.9)
Half-life (min)	9 (6 to 21)	26 (8 to 40)

* Area under the plasma galsulfase concentration-time curve from start of infusion to 60 minutes post infusion.

Galsulfase pharmacokinetic parameters listed in Table 2 require cautious interpretation because of large assay variability. Development of anti-galsulfase antibodies appears to affect galsulfase pharmacokinetics, however, the data are limited.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate carcinogenic potential or studies to evaluate mutagenic potential have not been performed with galsulfase.

Galsulfase at intravenous doses up to 3.0 mg/kg (about 0.5 times the recommended human dose of 1 mg/kg based on body surface area) was found to have no effect on the fertility and reproductive performance of male and female rats.

14 CLINICAL STUDIES

A total of 56 patients with MPS VI, ages 5 years to 29 years, were enrolled in four clinical studies. The majority of patients had severe manifestations of the disease as evidenced by poor performance on a test of physical endurance.

In the randomized, double-blind, multicenter, placebo-controlled clinical trial, 38 patients with MPS VI received 1 mg/kg NAGLAZYME or placebo, once-weekly for 24 weeks. The patients' ages ranged from 5 to 29 years. Enrollment was restricted to patients with a 12-minute walk distance of 5 to 400 meters. All patients were treated with antihistamines prior to each infusion.

The Naglazyme-treated group showed greater mean increases in the distance walked in 12 minutes (12-minute walk test, 12MWT) and in the rate of stair climbing in a 3-minute stair climb test, compared with the placebo group (Table 3).

Table 3: Results from Placebo-Controlled Clinical Study

	NAGLAZYME	Placebo	NAGLAZYME vs. Placebo

	Baseline	Week 24	Change	Baseline	Week 24	Change	Difference in Changes
N	19	19	19	20	19*	19	
Results from the 12-Minute Walk Test (Meters)							
Mean ± SD	227 ±170	336 ± 227	109 ± 154	381 ± 202	399 ± 217	26 ± 122	83 ± 45 [†] 92 ± 40 [‡] (p = 0.025) ^{‡§}
Median Percentiles (25 th , 75 th)	210 90, 330	316 125, 483	48 7, 183	365 256, 560	373 204, 573	34 -3, 89	
Results from 3-Minute Stair Climb Test (Stairs/Minute)							
Mean ± SD	19.4 ± 12.9	26.9 ± 16.8	7.4 ± 9.9	31.0 ± 18.1	32.6 ± 19.6	2.7 ± 6.9	4.7 ± 2.8 [†] 5.7 ± 2.9 [‡] (p = 0.053) ^{‡§}
Median Percentiles (25 th , 75 th)	16.7 10.0, 26.3	22.8 14.8, 33.0	5.2 2.2, 9.9	24.7 18.1, 51.5	29.0 14.2, 57.9	4.3 1.0, 6.2	

* One patient in the placebo group dropped out after 4 weeks of infusion

† Observed mean of NAGLAZYME - Placebo ± SE

‡ Model-based mean of NAGLAZYME - Placebo ± SE, adjusted for baseline

§ p-value based on the model-based mean difference

Following the 24-week placebo-controlled study period, 38 patients received open-label NAGLAZYME for 72 weeks. Among the 19 patients who were initially randomized to NAGLAZYME and who continued to receive treatment for 72 weeks (total of 96 weeks), increases in the 12-MWT distance and in the rate of stair climbing were observed compared to the start of the open-label period (mean [± SD] change): 72 ± 116 meters and 5.6 ± 10.6 stairs/minute, respectively). Among the 19 patients who were randomized initially to placebo for 24 weeks, and then crossed over to treatment with NAGLAZYME, the increases after 72 weeks of NAGLAZYME treatment compared to the start of the open-label period, (mean [± SD] change): were 118 ± 127 meters and 11.1 ± 10.0 stairs/minute, for the 12-MWT and the rate of stair climbing, respectively.

Bioactivity was evaluated with urinary GAG concentration. Overall, 95% of patients showed at least a 50% reduction in urinary GAG levels after 72 weeks of treatment with NAGLAZYME. No patient receiving NAGLAZYME reached the normal range for urinary GAG levels [see *Clinical Pharmacology (12.2)*].

In an additional open-label extension study, patients receiving NAGLAZYME showed maintenance of initial improvement in endurance for approximately 240 weeks.

16 HOW SUPPLIED/STORAGE AND HANDLING

NAGLAZYME is supplied as a sterile injection in clear Type I glass 5 mL vials, containing 5 mg galsulfase (expressed as protein content) per 5 mL solution. The closure consists of a siliconized chlorobutyl rubber stopper and an aluminum seal with a plastic flip-off cap.

NDC 68135-020-01, 5 mL vial

Store NAGLAZYME under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light. Do not use NAGLAZYME after the expiration date on the vial. This product contains no preservatives.

17 PATIENT COUNSELING INFORMATION

17.1 Infusion Reactions

Patients and caregivers should be counseled that reactions related to administration and infusion may occur during NAGLAZYME treatment, including life-threatening anaphylaxis. Premedication and reduction of infusion rate may alleviate those reactions associated with the infusion [*see Warnings and Precautions (5.4)*]

Patients should be advised to report any adverse reactions experienced while on NAGLAZYME treatment.

17.2 Clinical Surveillance Program

Patients should be informed that a Clinical Surveillance Program has been established in order to better understand the variability and progression of the disease in the population as a whole, and to monitor and evaluate long-term treatment effects of NAGLAZYME. The Clinical Surveillance Program will also monitor the effect of NAGLAZYME on pregnant women, nursing mothers and their offspring, and determine if NAGLAZYME is excreted in breast milk. Patients should be encouraged to participate and advised that their participation is voluntary and may involve long-term follow-up. For more information call 1-800-983-4587.

NAGLAZYME is manufactured and distributed by:
BioMarin Pharmaceutical Inc.
Novato, CA 94949
US License Number 1649
1-866-906-6100 (phone)

NAGLAZYME[®] is a registered trademark of BioMarin.

NDC 68135-020-01


Naglazyme[®]
(GALSULFASE)

5 mg/5 mL
(1 mg/mL)

Concentrated Solution For Intravenous Infusion Only

Must be diluted prior to use.

Rx Only



Naglazyme®
(GALSULFASE)

5 mg/5 mL
(1 mg/mL)

Concentrated Solution For Intravenous Infusion Only

Must be diluted prior to use.

Rx Only

D0624001/2 (11/13)
 (01)00368135020011

For single use only
 See package insert for dosage and administration.
 Store at 2 - 8°C (36 - 46°F)
 Do not freeze or shake

Manufactured and
 Distributed by:
 BioMarin Pharmaceutical Inc.
 Novato, CA 94949
 U.S. License No. 1649

BOMARIN®
 NDC 68135-020-01

Naglazyme®
 (GALSULFASE)

5 mg/5 mL (1 mg/mL)
**Concentrated Solution for
 Intravenous Infusion Only**
Must be diluted prior to use.
Rx Only



LOT:
 EXP:

NAGLAZYME

galsulfase solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68 135-020
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
GALSULFASE (UNII: 59UA429E5G) (GALSULFASE - UNII:59UA429E5G)	GALSULFASE	5 mg in 5 mL

Inactive Ingredients

Ingredient Name	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X)	43.8 mg in 5 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)	6.2 mg in 5 mL
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)	1.34 mg in 5 mL
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	0.25 mg in 5 mL
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68 135-020-01	1 in 1 CARTON	06/09/2005	
1		5 mL in 1 VIAL; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125117	06/09/2005	

Labeler - BioMarin Pharmaceutical Inc. (007004745)

Establishment

Name	Address	ID/FEI	Business Operations
AndersonBrecon (UK) Ltd.		762771269	LABEL(68135-020) , PACK(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
AndersonBrecon Inc.		053217022	LABEL(68135-020) , PACK(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
BioMarin International Limited		985066780	ANALYSIS(68135-020) , LABEL(68135-020) , PACK(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
BioMarin Pharmaceutical Inc.		010004135	ANALYSIS(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Catalent Pharma Solutions LLC		014904112	LABEL(68135-020) , PACK(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Catalent UK Packaging Limited		232616826	LABEL(68135-020) , PACK(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Envigo Analytics Limited		348277682	ANALYSIS(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Jubilant HollisterStier LLC		069263643	ANALYSIS(68135-020) , MANUFACTURE(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Vetter Pharma Fertigung GmbH & Co. KG		344217323	ANALYSIS(68135-020) , MANUFACTURE(68135-020)

Establishment

Name	Address	ID/FEI	Business Operations
Vetter Pharma Fertigung GmbH & Co. KG		316126754	ANALYSIS(68135-020)

Establishment			
Name	Address	ID/FEI	Business Operations
Vetter Pharma-Fertigung Gmbh & Co. KG		312670654	ANALYSIS(68135-020)

Establishment			
Name	Address	ID/FEI	Business Operations
Wickham Laboratories Ltd.		216813220	ANALYSIS(68135-020)

Revised: 3/2013

BioMarin Pharmaceutical Inc.